Form 4: Esperion Therapeutics CFO Benjamin Halladay Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 3,535 shares of common stock on March 18, 2025, to satisfy tax obligations related to vested restricted stock units.
Summary
- On March 18, 2025, Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc., sold 3,535 shares of the company's common stock.
- The sale was executed at a price of $1.483 per share.
- This transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Halladay directly owns 481,710 shares of Esperion Therapeutics.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine Form 4 filing, which is common for corporate insiders who buy or sell shares of their company's stock. It provides transparency into insider transactions.
Key Dates
| Date | Description |
|---|---|
| November 16, 2022 | Date of execution of the Limited Power of Attorney. |
| March 18, 2025 | Date of the stock sale transaction. |
| March 19, 2025 | Date of signature on the Form 4 filing. |
Keywords
Esperion Therapeutics, Benjamin Halladay, CFO, stock sale, Form 4, insider trading, tax obligations, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.